Bellshill, Glasgow, 29th October 2015 - Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical devices and pharmaceuticals, based on LamellasomeTM technology, that enables the creation of mimetics of extra-alveolar lamellar bodies, announces that its CEO Dr Alec McLean is to present at BIO-Europe 2015 in Munich.
Lamellar Biomedical has used its unique LamellasomeTM technology to create a development pipeline consisting of products to treat Radiotherapy Induced Xerostomia (RIX), Dry Eye disease and Cystic Fibrosis, all conditions which are poorly served by current treatment options.
Dr Alec McLean’s presentation at Bio-Europe will be entitled:
“Visco-ease – A Close to Market Medical Device for Radiotherapy Induced Xerostomia.”
The presentation will be part of the Cancer Stream keynote presentations and will take place at 17:30 on Tuesday 3rd November in Room 2 of the Munich International Congress Center.
The Company plans to begin a clinical study with Visco-ease, a medical device, in patients with RIX at the Beatson West of Scotland Cancer Centre before the end of 2015. The data from the study, which is expected in Q2 2016, will be used to support the product’s planned commercialisation in Europe in 2017.
Pre-clinical studies with Visco-ease conducted by the Beatson West of Scotland Cancer Centre were published in Supportive Care in Cancer (June 2015) showing that the product restores the functionality of the saliva of patients who were undergoing radiotherapy.
BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry and takes place 2-4 November 2015. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.
For further information, please contact:
Lamellar Biomedical
Dr Alec McLean
Citigate Dewe Rogerson
David Dible/ Pip Batty
david.dible@citigatedr.co.uk
About Lamellar Biomedical
Lamellar Biomedical is the only company globally focused on LamellasomeTM technology (micron-scale lipid vesicles) which have multiple medical applications.
Lamellar Biomedical’s development pipeline includes a number of patent-protected medical devices and pharmaceuticals targeting Radiotherapy Induced Xerostomia, Dry Eye Disease and Cystic Fibrosis. These are all conditions that are poorly served by current medications and therefore represent areas of high value unmet medical need.
LamellasomeTM technology produces mimetics of the body’s extra-alveolar lamellar bodies. These regulate the internal interfaces between human tissues as well as the interfaces between tissues and the external environment as in the mouth and lungs. They act biophysically are muco-restorative and have the potential to resolve a broad range of disease states that are associated with dry or sticky mucosal surfaces.
Lamellar Biomedical is based near Glasgow, Scotland. It has been financed by a range of investors including Invesco, Barwell, TRI Capital and Scottish Enterprise.
For more information please visit: www.lamellar.com
Help employers find you! Check out all the jobs and post your resume.
Lamellar Biomedical has used its unique LamellasomeTM technology to create a development pipeline consisting of products to treat Radiotherapy Induced Xerostomia (RIX), Dry Eye disease and Cystic Fibrosis, all conditions which are poorly served by current treatment options.
Dr Alec McLean’s presentation at Bio-Europe will be entitled:
“Visco-ease – A Close to Market Medical Device for Radiotherapy Induced Xerostomia.”
The presentation will be part of the Cancer Stream keynote presentations and will take place at 17:30 on Tuesday 3rd November in Room 2 of the Munich International Congress Center.
The Company plans to begin a clinical study with Visco-ease, a medical device, in patients with RIX at the Beatson West of Scotland Cancer Centre before the end of 2015. The data from the study, which is expected in Q2 2016, will be used to support the product’s planned commercialisation in Europe in 2017.
Pre-clinical studies with Visco-ease conducted by the Beatson West of Scotland Cancer Centre were published in Supportive Care in Cancer (June 2015) showing that the product restores the functionality of the saliva of patients who were undergoing radiotherapy.
BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry and takes place 2-4 November 2015. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.
For further information, please contact:
Lamellar Biomedical
Dr Alec McLean
Citigate Dewe Rogerson
David Dible/ Pip Batty
david.dible@citigatedr.co.uk
About Lamellar Biomedical
Lamellar Biomedical is the only company globally focused on LamellasomeTM technology (micron-scale lipid vesicles) which have multiple medical applications.
Lamellar Biomedical’s development pipeline includes a number of patent-protected medical devices and pharmaceuticals targeting Radiotherapy Induced Xerostomia, Dry Eye Disease and Cystic Fibrosis. These are all conditions that are poorly served by current medications and therefore represent areas of high value unmet medical need.
LamellasomeTM technology produces mimetics of the body’s extra-alveolar lamellar bodies. These regulate the internal interfaces between human tissues as well as the interfaces between tissues and the external environment as in the mouth and lungs. They act biophysically are muco-restorative and have the potential to resolve a broad range of disease states that are associated with dry or sticky mucosal surfaces.
Lamellar Biomedical is based near Glasgow, Scotland. It has been financed by a range of investors including Invesco, Barwell, TRI Capital and Scottish Enterprise.
For more information please visit: www.lamellar.com
Help employers find you! Check out all the jobs and post your resume.
